Brand Prescription Drugs to Rise an Average 4.5% in 2025
Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Sanofi (SNY.US) has applied for the market launch of BTK inhibitors in China.
On December 30, the CDE official website showed that Sanofi (SNY.US) has had its market application for the BTK inhibitor Rilzabrutinib accepted.
How Is The Market Feeling About Sanofi?
RTW Biotech Opportunities Unit Closes Rights Deal With Sanofi, Buys Investigational Drug
Sanofi Hits 5-week High
A Look Into Sanofi Inc's Price Over Earnings
AlphaValue/Baader Europe Trims Sanofi PT, Reiterates Buy Rating
The Zacks Analyst Blog Highlights ServiceNow, AMD, Sanofi, Team and United-Guardian
Top Research Reports for ServiceNow, AMD & Sanofi
Express News | Fulcrum Therapeutics Inc - Sanofi to Terminate Collaboration and License Agreement With Fulcrum
Sanofi Appoints Jean-Paul Kress to Board of Directors
Why Is Sanofi (SNY) Among the Best European Dividend Stocks To Buy Now?
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Sanofi, SK Bioscience Extend Collaboration to Develop Pneumococcal Disease Vaccine for Toddlers, Infants
Press Release: Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration With SK Bioscience for Next-generation Pneumococcal Conjugate Vaccines
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Sanofi Signs Deal for Greater China Rights to Aficamten
Sanofi's Tolebrutinib Receives FDA Breakthrough Therapy Designation for NrSPMS